STOCK TITAN

Vertex director gifts 6,000 company shares

VERTEX PHARMACEUTICALS INC / MA (VRTX) director Bruce I. Sachs reported a disposition of common stock through a bona fide gift.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

VERTEX PHARMACEUTICALS INC / MA (VRTX) director Bruce I. Sachs reported a disposition of common stock through a bona fide gift. On 2026-08-27, he transferred 6,000 shares of Vertex common stock, recorded at $0.00 per share for reporting purposes, and reported holding 39,000 shares directly afterward.

Positive

  • None.

Negative

  • None.
Insider SACHS BRUCE I
Role Director
Type Security Shares Price Value
Gift Common Stock 6,000 $0.00 $0.00
Holdings After Transaction: Common Stock — 39,000 shares (Direct)
Shares gifted 6,000 shares of Common Stock Bona fide gift reported on 2026-08-27
Price per share for reporting $0.00 per share Reported value for the 6,000-share bona fide gift
Shares held after transaction 39,000 shares of Common Stock Direct ownership following the 6,000-share gift
bona fide gift financial
"transaction_code_description: Bona fide gift"
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
beneficial ownership financial
"Total shares following transaction represents reported beneficial holdings"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What insider transaction did VRTX director Bruce I. Sachs report?

Bruce I. Sachs reported a bona fide gift of 6,000 shares of Vertex common stock on 2026-08-27, with no per-share consideration reported (shown as $0.00 for filing purposes).

How many VRTX shares did Bruce I. Sachs hold after the reported transaction?

After the 6,000-share bona fide gift on 2026-08-27, Bruce I. Sachs reported 39,000 shares of Vertex common stock held directly.

Was the VRTX transaction by Bruce I. Sachs a purchase or a sale?

It was neither a purchase nor a sale. The Form 4 reports a bona fide gift of 6,000 shares of Vertex common stock by director Bruce I. Sachs.

Did Bruce I. Sachs receive any cash consideration for the gifted VRTX shares?

No cash consideration is reported. The 6,000-share bona fide gift is shown at $0.00 per share in the Form 4, consistent with a non-cash transfer.

Does the Form 4 indicate trading under a Rule 10b5-1 plan for VRTX?

No. The document-level Rule 10b5-1 checkbox is not checked, and the reported transaction is a bona fide gift rather than an open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SACHS BRUCE I

(Last)(First)(Middle)
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVE

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/27/2026G6,000D$039,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Christiana Stevenson, Attorney-in-Fact08/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)